mloh77 personal page - To The Moon

mloh77

mloh77

No personal profile

23Follow

4Followers

0Topic

0Badge

2022-06-24

$8VI Holdings Ltd(8VI.AU)$😰😭

2021-09-02

$8VIC(8VI.AU)$Why keep dropping?

2021-07-15

$8VIC(8VI.AU)$Think long-term.

2021-07-10

Yes, more than 99% making losses. ?

@Tom_Jerry:$Meta Materials Inc.(MMAT)$估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。

2021-06-29

Go for it

2021-06-29

Good

Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop

2021-06-29

$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?

2021-06-28

$Meta Materials Inc.(MMAT)$Drop till what value?

2021-06-28

$Meta Materials Inc.(MMAT)$Why couldnt i sell?

2021-06-28

$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.

2021-06-24

$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?

2021-06-23

Slow and steady

2021-06-22

$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…

2021-06-22

$Tiger Brokers(TIGR)$Keep the faith

2021-06-22

$Fisher & Paykel Healthcare Corp. Ltd.(FSPKF)$Anyone bought this because of Investopia?

2021-06-22

To buy or not to buy?

2021-06-22

$Docusign(DOCU)$patience

2021-06-21

Crypto drop

Bitcoin Falls to Two-Week Low as China Cracks Down on Crypto

2021-06-21

Noted

Orphazyme rose more than 6% in premarket trading

2021-06-19

$Orphazyme A/S(ORPH)$Patience

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581752686297380","uuid":"3581752686297380","gmtCreate":1618658691258,"gmtModify":1623377470270,"name":"mloh77","pinyin":"mloh77","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":23,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9041526941,"gmtCreate":1656077685784,"gmtModify":1676535763451,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","listText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","text":"$8VI Holdings Ltd(8VI.AU)$😰😭","images":[{"img":"https://community-static.tradeup.com/news/781826516bf8bcd0f956dc8972f52255","width":"1170","height":"2532"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041526941","isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812305702,"gmtCreate":1630550391706,"gmtModify":1676530337716,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","text":"$8VIC(8VI.AU)$Why keep dropping?","images":[{"img":"https://static.tigerbbs.com/aa5451c54123e50683eb394180ce6caa","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812305702","isVote":1,"tweetType":1,"viewCount":900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144489240,"gmtCreate":1626310111780,"gmtModify":1703757542580,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","text":"$8VIC(8VI.AU)$Think long-term.","images":[{"img":"https://static.tigerbbs.com/a3f5c4ee61f02feda0f31a0adcd6c7ca","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/144489240","isVote":1,"tweetType":1,"viewCount":885,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3562206499105387","authorId":"3562206499105387","name":"CY_Ng","avatar":"https://static.tigerbbs.com/eba016392472f02387b5ae5505dbc524","crmLevel":5,"crmLevelSwitch":1,"idStr":"3562206499105387","authorIdStr":"3562206499105387"},"content":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","text":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","html":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141575362,"gmtCreate":1625883146456,"gmtModify":1703750373331,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Yes, more than 99% making losses. ?","listText":"Yes, more than 99% making losses. ?","text":"Yes, more than 99% making losses. ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141575362","repostId":"141259623","repostType":1,"repost":{"id":141259623,"gmtCreate":1625876519462,"gmtModify":1703750190921,"author":{"id":"3571209718541642","authorId":"3571209718541642","name":"Tom_Jerry","avatar":"https://static.tigerbbs.com/5ce158ae76ab06ae07b990f57e8ced26","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571209718541642","authorIdStr":"3571209718541642"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","text":"$Meta Materials Inc.(MMAT)$估計很多人跟我一樣都是負數，希望它能慢慢回升，給支持它的人信心。下週加油⛽。","images":[{"img":"https://static.tigerbbs.com/41f0634abcad01d37e0cedf08f37544f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141259623","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159502528,"gmtCreate":1624973378164,"gmtModify":1703849137568,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Go for it","listText":"Go for it","text":"Go for it","images":[{"img":"https://static.tigerbbs.com/888b7250f82b7098d9fd7b887179688d","width":"750","height":"2216"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159502528","isVote":1,"tweetType":1,"viewCount":386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159506962,"gmtCreate":1624973270756,"gmtModify":1703849135786,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159506962","repostId":"1104222469","repostType":2,"repost":{"id":"1104222469","kind":"news","pubTimestamp":1624956846,"share":"https://ttm.financial/m/news/1104222469?lang=&edition=fundamental","pubTime":"2021-06-29 16:54","market":"us","language":"en","title":"Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop","url":"https://stock-news.laohu8.com/highlight/detail?id=1104222469","media":"InvestorPlace","summary":"CLOV tops the list with a 97.88 rating\nShort squeeze stocks have been targeted quite a bit lately as","content":"<p>CLOV tops the list with a 97.88 rating</p>\n<p>Short squeeze stocks have been targeted quite a bit lately as Reddit and retail traders tackle them in an effort to push out hedge funds and ramp up prices.</p>\n<p>As such, it comes as no surprise that some experts are laying out their best bets for short squeeze stocks. That includes Fintel, which released an updated list of stocks with short squeeze potential on Sunday.</p>\n<p>The list from Fintel takes a look at various points of data to determine if a stock has short squeeze potential. It also ranks these stocks on a zero to 100 scale in relation to their peers.</p>\n<p>Let’s take a look at the stocks that&nbsp;Fintel believes are ready for a short squeeze&nbsp;below!</p>\n<p><b>Short Squeeze Stocks to Watch</b></p>\n<ol>\n <li><b>Clover Health Investments</b>(NASDAQ:<b><u>CLOV</u></b>) stock starts the list with a 97.88 rating as shares climb slightly higher in early morning trading today.</li>\n <li><b>Alset Ehome International Inc</b>(NASDAQ:<b><u>AEI</u></b>) shares join the short squeeze list with a 97.38 rating as they dip over 2% lower Monday morning.</li>\n <li><b>Cellect Biotechnology</b>(NASDAQ:<b><u>APOP</u></b>) stock is just below it with a rating of 97.36 and shares seeing a slight drop as of this writing.</li>\n <li><b>Orphazyme A/S</b>(NASDAQ:<b><u>ORPH</u></b>) shares are up next with a 95.96 rating as they fall over 3% this morning.</li>\n <li><b>Digital Brands Group</b>(NASDAQ:<b><u>DBGI</u></b>) stock closes out the short squeeze list from Fintel with a 95.86 rating and the stock falling more than 14%.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 16:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/short-squeeze-stocks-clov-aei-and-3-other-stocks-experts-think-are-ready-to-pop/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CLOV tops the list with a 97.88 rating\nShort squeeze stocks have been targeted quite a bit lately as Reddit and retail traders tackle them in an effort to push out hedge funds and ramp up prices.\nAs ...</p>\n\n<a href=\"https://investorplace.com/2021/06/short-squeeze-stocks-clov-aei-and-3-other-stocks-experts-think-are-ready-to-pop/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AEI":"Alset EHome International Inc.","DBGI":"Digital Brands Group, Inc.","CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/short-squeeze-stocks-clov-aei-and-3-other-stocks-experts-think-are-ready-to-pop/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104222469","content_text":"CLOV tops the list with a 97.88 rating\nShort squeeze stocks have been targeted quite a bit lately as Reddit and retail traders tackle them in an effort to push out hedge funds and ramp up prices.\nAs such, it comes as no surprise that some experts are laying out their best bets for short squeeze stocks. That includes Fintel, which released an updated list of stocks with short squeeze potential on Sunday.\nThe list from Fintel takes a look at various points of data to determine if a stock has short squeeze potential. It also ranks these stocks on a zero to 100 scale in relation to their peers.\nLet’s take a look at the stocks that Fintel believes are ready for a short squeeze below!\nShort Squeeze Stocks to Watch\n\nClover Health Investments(NASDAQ:CLOV) stock starts the list with a 97.88 rating as shares climb slightly higher in early morning trading today.\nAlset Ehome International Inc(NASDAQ:AEI) shares join the short squeeze list with a 97.38 rating as they dip over 2% lower Monday morning.\nCellect Biotechnology(NASDAQ:APOP) stock is just below it with a rating of 97.36 and shares seeing a slight drop as of this writing.\nOrphazyme A/S(NASDAQ:ORPH) shares are up next with a 95.96 rating as they fall over 3% this morning.\nDigital Brands Group(NASDAQ:DBGI) stock closes out the short squeeze list from Fintel with a 95.86 rating and the stock falling more than 14%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159136184,"gmtCreate":1624947030748,"gmtModify":1703848599718,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","listText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","text":"$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?","images":[{"img":"https://static.tigerbbs.com/f59c64927d47ce5bbdea971b87b4de3d","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/3d4bc6dcded30256a44196b8500600c8","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/7140f78193b3385d27328f29726c6aea","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159136184","isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":150820489,"gmtCreate":1624893360541,"gmtModify":1703847370955,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","text":"$Meta Materials Inc.(MMAT)$Drop till what value?","images":[{"img":"https://static.tigerbbs.com/7501f655659eda862070fa5820ada76b","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150820489","isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150062098,"gmtCreate":1624876321614,"gmtModify":1703846787061,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","text":"$Meta Materials Inc.(MMAT)$Why couldnt i sell?","images":[{"img":"https://static.tigerbbs.com/9df6ebab45c76fec31572ae685a1cc69","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/150062098","isVote":1,"tweetType":1,"viewCount":2783,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127466900,"gmtCreate":1624864391600,"gmtModify":1703846498472,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","text":"$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","images":[{"img":"https://static.tigerbbs.com/bad92c5b105da0f6c28f4ceddb2cced6","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127466900","isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":128093601,"gmtCreate":1624494631003,"gmtModify":1703838213098,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","listText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","text":"$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?","images":[{"img":"https://static.tigerbbs.com/a7437c8a39c054aa2a45c36063315d19","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128093601","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":123301731,"gmtCreate":1624408016023,"gmtModify":1703835665278,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Slow and steady","listText":"Slow and steady","text":"Slow and steady","images":[{"img":"https://static.tigerbbs.com/dd724599fae65e2928972a9d86670445","width":"750","height":"1743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123301731","isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129663474,"gmtCreate":1624371212298,"gmtModify":1703834745572,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","text":"$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…","images":[{"img":"https://static.tigerbbs.com/ab023e422668b123bc4abb809f4f8ae4","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/129663474","isVote":1,"tweetType":1,"viewCount":1603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129128525,"gmtCreate":1624366007367,"gmtModify":1703834476370,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","text":"$Tiger Brokers(TIGR)$Keep the faith","images":[{"img":"https://static.tigerbbs.com/506220a9dd82cf8d5c9db2443fecc06b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/129128525","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129129436,"gmtCreate":1624365875725,"gmtModify":1703834472311,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FSPKF\">$Fisher &amp; Paykel Healthcare Corp. Ltd.(FSPKF)$</a>Anyone&nbsp;bought this because of Investopia?","listText":"<a href=\"https://laohu8.com/S/FSPKF\">$Fisher &amp; Paykel Healthcare Corp. Ltd.(FSPKF)$</a>Anyone&nbsp;bought this because of Investopia?","text":"$Fisher & Paykel Healthcare Corp. Ltd.(FSPKF)$Anyone bought this because of Investopia?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129129436","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129181361,"gmtCreate":1624365103753,"gmtModify":1703834446987,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"To buy or not to buy?","listText":"To buy or not to buy?","text":"To buy or not to buy?","images":[{"img":"https://static.tigerbbs.com/064c9e4cea9eefb35e2f8e8ce664260a","width":"750","height":"2216"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129181361","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129189815,"gmtCreate":1624365032137,"gmtModify":1703834444556,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","listText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","text":"$Docusign(DOCU)$patience","images":[{"img":"https://static.tigerbbs.com/54995e5c1554ec254eaa32ca807c5196","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129189815","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167269139,"gmtCreate":1624271257921,"gmtModify":1703832065195,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Crypto drop","listText":"Crypto drop","text":"Crypto drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167269139","repostId":"1147979715","repostType":4,"repost":{"id":"1147979715","kind":"news","pubTimestamp":1624270382,"share":"https://ttm.financial/m/news/1147979715?lang=&edition=fundamental","pubTime":"2021-06-21 18:13","market":"fut","language":"en","title":"Bitcoin Falls to Two-Week Low as China Cracks Down on Crypto","url":"https://stock-news.laohu8.com/highlight/detail?id=1147979715","media":"Bloomberg","summary":"Bitcoin trades near $33,000 amid worries over market froth\nChina’s harder regulatory stance on crypt","content":"<ul>\n <li>Bitcoin trades near $33,000 amid worries over market froth</li>\n <li>China’s harder regulatory stance on crypto is rattling traders</li>\n</ul>\n<p>Bitcoin fell to a two-week low amid an intensifying cryptocurrency crackdown in China.</p>\n<p>The largest virtual currency fell 8% to $33,070 as of 11:12 a.m. in London. Ether declined 12% to $1,993.</p>\n<p>China has ordered payment platform Alipay and domestic banks to not to provide services linked to trading of virtual currencies. The institutions were also ordered to cut off payment channels for crypto exchanges and over-the-counter platforms, the People’s Bank of China said in a statement.</p>\n<p>It’s more evidence of China’s tougher stance on crypto that’s stretching from financial regulation to the energy demands of Bitcoin mining.</p>\n<p>“The PBOC crackdown is going further than initially expected,” said Jonathan Cheesman, head of over-the-counter and institutional sales at crypto derivatives exchange FTX. “Mining was phase one and speculation is phase two.”</p>\n<p><img src=\"https://static.tigerbbs.com/31559c8718fe04732604f944b234261f\" tg-width=\"1200\" tg-height=\"675\"></p>\n<p>Separately, a Chinese city with abundant hydropower has stepped up action to rein in mining. A Ya’an government official told at least one Bitcoin miner that the city has promised to root out all Bitcoin and Ether mining operations with a year, said a person with knowledge of the situation.</p>\n<p>In the backdrop, the appetite for risk assets has diminished after last week’s hawkish policy pivot by the Federal Reserve. Even though equity markets tipped into the green on Monday, analysts pointed to lingering jitters about frothy corners of the market.</p>\n<p>“If, as I expect, the global buy-everything unwind continues this week, Bitcoin willfeelthose chill winds,” said Jeffrey Halley, senior market analyst at Oanda Asia Pacific Pte.</p>\n<p>Some commentators have said China’s hashrate -- the computational power used to mine coins and process blockchain transactions -- is waning amid harsher regulatory oversight.</p>\n<p>The crypto faithful are also grappling with a tumble in tokens used in so-called&nbsp;decentralized-finance-- or DeFi -- applications. DeFi apps let people lend, borrow, trade and take out insurance directly from each other using blockchain technology, without use of intermediaries such as banks.</p>\n<p>For instance, the DeFi Titanium token went from being valued at around $60 to $0 -- a rare occurrence even for famously volatile crypto markets. Famed mogul Mark Cuban had invested, telling Bloomberg News earlier that though it represented a small percentage of his crypto portfolio, the wipe-out “was enough that I wasn’t happy about it.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin Falls to Two-Week Low as China Cracks Down on Crypto</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin Falls to Two-Week Low as China Cracks Down on Crypto\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 18:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-21/bitcoin-pressured-by-post-fed-dip-in-sentiment-china-crackdown?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bitcoin trades near $33,000 amid worries over market froth\nChina’s harder regulatory stance on crypto is rattling traders\n\nBitcoin fell to a two-week low amid an intensifying cryptocurrency crackdown ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-21/bitcoin-pressured-by-post-fed-dip-in-sentiment-china-crackdown?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-21/bitcoin-pressured-by-post-fed-dip-in-sentiment-china-crackdown?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147979715","content_text":"Bitcoin trades near $33,000 amid worries over market froth\nChina’s harder regulatory stance on crypto is rattling traders\n\nBitcoin fell to a two-week low amid an intensifying cryptocurrency crackdown in China.\nThe largest virtual currency fell 8% to $33,070 as of 11:12 a.m. in London. Ether declined 12% to $1,993.\nChina has ordered payment platform Alipay and domestic banks to not to provide services linked to trading of virtual currencies. The institutions were also ordered to cut off payment channels for crypto exchanges and over-the-counter platforms, the People’s Bank of China said in a statement.\nIt’s more evidence of China’s tougher stance on crypto that’s stretching from financial regulation to the energy demands of Bitcoin mining.\n“The PBOC crackdown is going further than initially expected,” said Jonathan Cheesman, head of over-the-counter and institutional sales at crypto derivatives exchange FTX. “Mining was phase one and speculation is phase two.”\n\nSeparately, a Chinese city with abundant hydropower has stepped up action to rein in mining. A Ya’an government official told at least one Bitcoin miner that the city has promised to root out all Bitcoin and Ether mining operations with a year, said a person with knowledge of the situation.\nIn the backdrop, the appetite for risk assets has diminished after last week’s hawkish policy pivot by the Federal Reserve. Even though equity markets tipped into the green on Monday, analysts pointed to lingering jitters about frothy corners of the market.\n“If, as I expect, the global buy-everything unwind continues this week, Bitcoin willfeelthose chill winds,” said Jeffrey Halley, senior market analyst at Oanda Asia Pacific Pte.\nSome commentators have said China’s hashrate -- the computational power used to mine coins and process blockchain transactions -- is waning amid harsher regulatory oversight.\nThe crypto faithful are also grappling with a tumble in tokens used in so-called decentralized-finance-- or DeFi -- applications. DeFi apps let people lend, borrow, trade and take out insurance directly from each other using blockchain technology, without use of intermediaries such as banks.\nFor instance, the DeFi Titanium token went from being valued at around $60 to $0 -- a rare occurrence even for famously volatile crypto markets. Famed mogul Mark Cuban had invested, telling Bloomberg News earlier that though it represented a small percentage of his crypto portfolio, the wipe-out “was enough that I wasn’t happy about it.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167260927,"gmtCreate":1624271213869,"gmtModify":1703832068046,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167260927","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162128293,"gmtCreate":1624045699512,"gmtModify":1703827522762,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581752686297380","authorIdStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","text":"$Orphazyme A/S(ORPH)$Patience","images":[{"img":"https://static.tigerbbs.com/82df7e0afaf3a94bb43b6a376ce627b9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/162128293","isVote":1,"tweetType":1,"viewCount":1432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":162128293,"gmtCreate":1624045699512,"gmtModify":1703827522762,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>Patience","text":"$Orphazyme A/S(ORPH)$Patience","images":[{"img":"https://static.tigerbbs.com/82df7e0afaf3a94bb43b6a376ce627b9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/162128293","isVote":1,"tweetType":1,"viewCount":1432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129663474,"gmtCreate":1624371212298,"gmtModify":1703834745572,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>How low will it go? I average down from $17 to $6…","text":"$Orphazyme A/S(ORPH)$How low will it go? I average down from $17 to $6…","images":[{"img":"https://static.tigerbbs.com/ab023e422668b123bc4abb809f4f8ae4","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/129663474","isVote":1,"tweetType":1,"viewCount":1603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181871509,"gmtCreate":1623387131101,"gmtModify":1704202275620,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Record","listText":"Record","text":"Record","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181871509","repostId":"1184070773","repostType":4,"repost":{"id":"1184070773","kind":"news","pubTimestamp":1623367038,"share":"https://ttm.financial/m/news/1184070773?lang=&edition=fundamental","pubTime":"2021-06-11 07:17","market":"us","language":"en","title":"S&P 500 climbs to a new record close, shrugging off inflation fears","url":"https://stock-news.laohu8.com/highlight/detail?id=1184070773","media":"cnbc","summary":"The S&P 500 rose to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.The broad equity benchmark climbed nearly 0.5% to a record closing high of 4,239.18. The S&P 500 also hit an intraday record of 4,249.74, overtaking its May 7 high after the market traded sideways for a month. The Dow Jones Industrial Average advanced 19.10 points, or less than 0.1%, to 34,466.24, while the Nasdaq Composite gained about ","content":"<div>\n<p>The S&P 500 rose to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark climbed ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 climbs to a new record close, shrugging off inflation fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 climbs to a new record close, shrugging off inflation fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 07:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 rose to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark climbed ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站",".DJI":"道琼斯","UPS":"联合包裹",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1184070773","content_text":"The S&P 500 rose to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark climbed nearly 0.5% to a record closing high of 4,239.18. The S&P 500 also hit an intraday record of 4,249.74, overtaking its May 7 high after the market traded sideways for a month. The Dow Jones Industrial Average advanced 19.10 points, or less than 0.1%, to 34,466.24, while the Nasdaq Composite gained about 0.8% to 14,020.33.\nConsumer prices for May accelerated at their fastest pace since the summer of 2008 amid the economic recovery from the pandemic-triggered recession,the Labor Department reported Thursday.\nThe consumer price index, which represents a basket including food, energy, groceries and prices across a spectrum of goods, rose 5% from a year ago. Economists surveyed by Dow Jones had been expecting a gain of 4.7%.\n\"I think there were a lot of people who held back, who wanted to see the hotter inflation number,\" CNBC's Jim Cramer said on \"Squawk on the Street.\" \"Now they've said, 'OK, now that's over with. Let's do some buying.' Because they've been on the sideline and they want to get in. I don't think that's actually usual these days because there's still so much buying power out there. People want in.\"\nFears of spiking inflation have weighed on the stock market in the last month, with investors worried the jump in prices will raise costs for companies, spark a move higher in interest rates and cause the Federal Reserve to remove its easy money policies.\n\"This CPI isn't likely to change the narrative dramatically, and there are still indications that inflation momentum is set to abate in the coming months,\" Adam Crisafulli, founder of Vital Knowledge, said in a note Thursday.\nMany economists also said the surge in used car costs for the month could have skewed the inflation reading. Used car and truck prices jumped more than 7%, accounting for one-third of the total increase for the month, according to the Bureau of Labor Statistics. The jump in used car prices likely reflects a temporary phenomenon related to the pandemic and auto supply.\nA separate report released Thursday showed that jobless claims for the week ended June 5 came in at 376,000, versus a Dow Jones estimate of 370,000. The total still marked the lowest of the pandemic era.\nUPS shares rose about 1% afteran upgrade from JPMorgan. Shares of Boeing were higher, but Delta Air Lines slipped.\nVideo-game retailer and meme stock GameStop fell 27% even after the company tapped former Amazon executive Matt Furlong to be its next CEO and said that sales rose 25% last quarter. The company also said it may sell up to 5 million additional shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571630433284403","authorId":"3571630433284403","name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3571630433284403","idStr":"3571630433284403"},"content":"comment plz","text":"comment plz","html":"comment plz"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187912378,"gmtCreate":1623734386494,"gmtModify":1704209941760,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Yayness! reach 5 dollars ?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Yayness! reach 5 dollars ?","text":"$8VIC(8VI.AU)$Yayness! reach 5 dollars ?","images":[{"img":"https://static.tigerbbs.com/9d9f6b5d60ae5a5d622c2ba25788d5cf","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/187912378","isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3577855760701774","authorId":"3577855760701774","name":"fredke","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"3577855760701774","idStr":"3577855760701774"},"content":"coming to $6 today!","text":"coming to $6 today!","html":"coming to $6 today!"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150062098,"gmtCreate":1624876321614,"gmtModify":1703846787061,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Why couldnt i sell?","text":"$Meta Materials Inc.(MMAT)$Why couldnt i sell?","images":[{"img":"https://static.tigerbbs.com/9df6ebab45c76fec31572ae685a1cc69","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/150062098","isVote":1,"tweetType":1,"viewCount":2783,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":169005679,"gmtCreate":1623808155991,"gmtModify":1703820068752,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Rocket","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Rocket","text":"$8VIC(8VI.AU)$Rocket","images":[{"img":"https://static.tigerbbs.com/34fa198ad09eee4f47226c9358d8bc75","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169005679","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129128525,"gmtCreate":1624366007367,"gmtModify":1703834476370,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Keep the faith","text":"$Tiger Brokers(TIGR)$Keep the faith","images":[{"img":"https://static.tigerbbs.com/506220a9dd82cf8d5c9db2443fecc06b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/129128525","isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":184497541,"gmtCreate":1623720968083,"gmtModify":1704209500396,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Accumulate","listText":"Accumulate","text":"Accumulate","images":[{"img":"https://static.tigerbbs.com/1de9a2958afe92e5c342e5f99c2bbd8f","width":"750","height":"1743"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/184497541","isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581467266860645","authorId":"3581467266860645","name":"Newbiecub","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3581467266860645","idStr":"3581467266860645"},"content":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?","text":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?","html":"Is there an intRinsic value chart for 8ih in VI App? How u find the app so far?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144489240,"gmtCreate":1626310111780,"gmtModify":1703757542580,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Think long-term.","text":"$8VIC(8VI.AU)$Think long-term.","images":[{"img":"https://static.tigerbbs.com/a3f5c4ee61f02feda0f31a0adcd6c7ca","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/144489240","isVote":1,"tweetType":1,"viewCount":885,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3562206499105387","authorId":"3562206499105387","name":"CY_Ng","avatar":"https://static.tigerbbs.com/eba016392472f02387b5ae5505dbc524","crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3562206499105387","idStr":"3562206499105387"},"content":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","text":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting.","html":"the hype is finish. company need to deliver more exciting result to push the share price further up. latest report is not that exciting."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9041526941,"gmtCreate":1656077685784,"gmtModify":1676535763451,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","listText":"<a href=\"https://ttm.financial/S/8VI.AU\">$8VI Holdings Ltd(8VI.AU)$</a>😰😭","text":"$8VI Holdings Ltd(8VI.AU)$😰😭","images":[{"img":"https://community-static.tradeup.com/news/781826516bf8bcd0f956dc8972f52255","width":"1170","height":"2532"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041526941","isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161427296,"gmtCreate":1623938774215,"gmtModify":1703824041815,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>stay cool","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>stay cool","text":"$Orphazyme A/S(ORPH)$stay cool","images":[{"img":"https://static.tigerbbs.com/288ca559b16ab880152e95b6ee86f160","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161427296","isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186861256,"gmtCreate":1623485206975,"gmtModify":1704204935935,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>??","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>??","text":"$Orphazyme A/S(ORPH)$??","images":[{"img":"https://static.tigerbbs.com/486a0e1bb80cd970271e4781e5901a16","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/186861256","isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812305702,"gmtCreate":1630550391706,"gmtModify":1676530337716,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","listText":"<a href=\"https://laohu8.com/S/8VI.AU\">$8VIC(8VI.AU)$</a>Why keep dropping?","text":"$8VIC(8VI.AU)$Why keep dropping?","images":[{"img":"https://static.tigerbbs.com/aa5451c54123e50683eb394180ce6caa","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812305702","isVote":1,"tweetType":1,"viewCount":900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150820489,"gmtCreate":1624893360541,"gmtModify":1703847370955,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Meta Materials Inc.(MMAT)$</a>Drop till what value?","text":"$Meta Materials Inc.(MMAT)$Drop till what value?","images":[{"img":"https://static.tigerbbs.com/7501f655659eda862070fa5820ada76b","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150820489","isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127466900,"gmtCreate":1624864391600,"gmtModify":1703846498472,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","listText":"<a href=\"https://laohu8.com/S/MMAT\">$Torchlight Energy Resources Inc(MMAT)$</a>My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","text":"$Torchlight Energy Resources Inc(MMAT)$My 200 shares will become 100 shares. Average cost of $5.38 will become $10.76.","images":[{"img":"https://static.tigerbbs.com/bad92c5b105da0f6c28f4ceddb2cced6","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/127466900","isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":129189815,"gmtCreate":1624365032137,"gmtModify":1703834444556,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","listText":"<a href=\"https://laohu8.com/S/DOCU\">$Docusign(DOCU)$</a>patience","text":"$Docusign(DOCU)$patience","images":[{"img":"https://static.tigerbbs.com/54995e5c1554ec254eaa32ca807c5196","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129189815","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181879150,"gmtCreate":1623387053770,"gmtModify":1704202273190,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Very volatile.","listText":"Very volatile.","text":"Very volatile.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181879150","repostId":"2142278359","repostType":4,"repost":{"id":"2142278359","kind":"news","pubTimestamp":1623382532,"share":"https://ttm.financial/m/news/2142278359?lang=&edition=fundamental","pubTime":"2021-06-11 11:35","market":"us","language":"en","title":"AMC Investors Hit Sell Button amid Meme-Stock Meltdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2142278359","media":"FX Empire","summary":"Meme stocks are having a tough day, and AMC Entertainment is among the hardest-hit names. Shares of ","content":"<p>Meme stocks are having a tough day, and AMC Entertainment is among the hardest-hit names. Shares of the movie chain are down nearly 13% amid a sell-off in the entire group today.</p>\n<p>After AMC shares traded as high as USD 62.55 in early June, they have since proceeded to give back ground as investors watched 30% get shaved from the stock’s value.</p>\n<p><img src=\"https://static.tigerbbs.com/6861b0eb0095f5028a03ac40c37f39cd\" tg-width=\"800\" tg-height=\"319\" referrerpolicy=\"no-referrer\"></p>\n<h2>Short Interest Persists</h2>\n<p>Short selling activity in AMC remains robust , with short interest hovering at 102.3 million shares as of May 28, as per exchange data cited by financial analytics firm Ortex. The short interest surpassed expectations considering that traders have lost billions of dollars to the WallStreetBets movement as retail investors have gained the upper hand.</p>\n<p>With the latest exchange data, AMC’s short interest is estimated to be 12.7% of the stock’s free float, according to Ortex. Short interest in AMC has been as high as 18% recently.</p>\n<h2>Insider Selling</h2>\n<p>A couple of significant AMC investors have decided to profit from the latest meme stock craze and cash in some of their holdings. Among them, Howard Koch Jr., the producer of popular flicks including Wayne’s World and Primal Fear, has unloaded more than 14,000 shares in recent days, an SEC filing reveals.</p>\n<p>After selling shares at an average price of USD 55.34, he saw a payday of more than USD 790K. Koch, who is also known as Hawk, still owns tens of thousands of shares in the movie stock. Before this month, he hadn’t hit the sell button on the stock in half a decade.</p>\n<p>In addition, there was some insider selling. AMC HR executive Carla Chavarria parted ways with more than 40,000 shares of her employer’s stock at an average price of USD 62.67. She took home USD 2.5 million.</p>\n<h2>Meme Stock Meltdown</h2>\n<p>Selling today isn’t limited to AMC and has spilled over into several meme-stock names, even the newer ones. GameStop shares are down an eye-popping 20% after the company’s earnings report left investors wanting greater transparency on the rest of the year. BlackBerry, Clover Health and Wendy’s are also under pressure today.</p>\n<p>As long as the broader stock market remains stuck in its current narrow range, however, the meme stock’s glory days are likely not over yet as investors hunt returns, according to OANDA senior market analyst Edward Moya.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Investors Hit Sell Button amid Meme-Stock Meltdown</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Investors Hit Sell Button amid Meme-Stock Meltdown\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amc-investors-hit-sell-button-174032182.html><strong>FX Empire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme stocks are having a tough day, and AMC Entertainment is among the hardest-hit names. Shares of the movie chain are down nearly 13% amid a sell-off in the entire group today.\nAfter AMC shares ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amc-investors-hit-sell-button-174032182.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","BB":"黑莓","GME":"游戏驿站"},"source_url":"https://finance.yahoo.com/news/amc-investors-hit-sell-button-174032182.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142278359","content_text":"Meme stocks are having a tough day, and AMC Entertainment is among the hardest-hit names. Shares of the movie chain are down nearly 13% amid a sell-off in the entire group today.\nAfter AMC shares traded as high as USD 62.55 in early June, they have since proceeded to give back ground as investors watched 30% get shaved from the stock’s value.\n\nShort Interest Persists\nShort selling activity in AMC remains robust , with short interest hovering at 102.3 million shares as of May 28, as per exchange data cited by financial analytics firm Ortex. The short interest surpassed expectations considering that traders have lost billions of dollars to the WallStreetBets movement as retail investors have gained the upper hand.\nWith the latest exchange data, AMC’s short interest is estimated to be 12.7% of the stock’s free float, according to Ortex. Short interest in AMC has been as high as 18% recently.\nInsider Selling\nA couple of significant AMC investors have decided to profit from the latest meme stock craze and cash in some of their holdings. Among them, Howard Koch Jr., the producer of popular flicks including Wayne’s World and Primal Fear, has unloaded more than 14,000 shares in recent days, an SEC filing reveals.\nAfter selling shares at an average price of USD 55.34, he saw a payday of more than USD 790K. Koch, who is also known as Hawk, still owns tens of thousands of shares in the movie stock. Before this month, he hadn’t hit the sell button on the stock in half a decade.\nIn addition, there was some insider selling. AMC HR executive Carla Chavarria parted ways with more than 40,000 shares of her employer’s stock at an average price of USD 62.67. She took home USD 2.5 million.\nMeme Stock Meltdown\nSelling today isn’t limited to AMC and has spilled over into several meme-stock names, even the newer ones. GameStop shares are down an eye-popping 20% after the company’s earnings report left investors wanting greater transparency on the rest of the year. BlackBerry, Clover Health and Wendy’s are also under pressure today.\nAs long as the broader stock market remains stuck in its current narrow range, however, the meme stock’s glory days are likely not over yet as investors hunt returns, according to OANDA senior market analyst Edward Moya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159136184,"gmtCreate":1624947030748,"gmtModify":1703848599718,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","listText":"<a href=\"https://laohu8.com/S/RRL.AU\">$Regis Resources Ltd(RRL.AU)$</a>Every method shows its undervalued, so why&nbsp;price keeps dropping?","text":"$Regis Resources Ltd(RRL.AU)$Every method shows its undervalued, so why price keeps dropping?","images":[{"img":"https://static.tigerbbs.com/f59c64927d47ce5bbdea971b87b4de3d","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/3d4bc6dcded30256a44196b8500600c8","width":"828","height":"1792"},{"img":"https://static.tigerbbs.com/7140f78193b3385d27328f29726c6aea","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159136184","isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":128093601,"gmtCreate":1624494631003,"gmtModify":1703838213098,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","listText":"<a href=\"https://laohu8.com/S/PME.AU\">$Pro Medicus Ltd(PME.AU)$</a>Who else is here because of Investopia?","text":"$Pro Medicus Ltd(PME.AU)$Who else is here because of Investopia?","images":[{"img":"https://static.tigerbbs.com/a7437c8a39c054aa2a45c36063315d19","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128093601","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167260927,"gmtCreate":1624271213869,"gmtModify":1703832068046,"author":{"id":"3581752686297380","authorId":"3581752686297380","name":"mloh77","avatar":"https://static.tigerbbs.com/01590b23793ed123fade949ec8bb1c7e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581752686297380","idStr":"3581752686297380"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167260927","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}